Analysis of antitumor activity elicited by vaccination with combinations of interleukin-12 DNA with gp100 DNA or the chemokine CCL21 in vivo

Human Gene Therapy

Volumn 17, Issue 8, 2006, Pages 859-870

  Elzaouk, Lina ^a   Pavlovic, Jovan ^a   Moelling, Karin ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; IMMUNOMODULATING AGENT; MELANOMA ANTIGEN; PROTEIN HGP100; RECOMBINANT INTERLEUKIN 12; SECONDARY LYMPHOID TISSUE CHEMOKINE; UNCLASSIFIED DRUG; BETA CHEMOKINE; CANCER VACCINE; DNA VACCINE; INTERLEUKIN 12; MELANOCYTE LINEAGE SPECIFIC ANTIGEN GP100; MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100; MEMBRANE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA BINDING; DRUG EFFICACY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; T LYMPHOCYTE; VACCINATION; XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; ISOGRAFT; METHODOLOGY; TUMOR CELL LINE;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CHEMOKINES, CC; FEMALE; HUMANS; INTERLEUKIN-12; MELANOMA; MEMBRANE GLYCOPROTEINS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; TRANSPLANTATION, HETEROLOGOUS; TRANSPLANTATION, ISOGENEIC; VACCINATION; VACCINES, DNA;

EID: 33750588236     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.859     Document Type: Article

References (32)

1. ANGIOLILLO, A.L., SGADARI, C., TAUB, D.D., LIAO, F., FARBER, J.M., MAHESHWARI, S., KLEINMAN, H.K., REAMAN, G.H., and TOSATO, G. (1995). Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182, 155-162.
2. ARENBERG, D.A., ZLOTNICK, A., STROM, S.R., BURDICK, M.D., and STRIETER, R.M. (2001). The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model. Cancer Immunol. Immunother. 49, 587-592.
3. BRAUN, S.E., CHEN, K., FOSTER, R.G., KIM, C.H., HROMAS, R., KAPLAN, M.H., BROXMEYER, H.E., and CORNETTA, K. (2000). The CC chemokine CK β-11/MIP-3 β/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J. Immunol. 164, 4025-4031.
4. CYSTER, J.G. (1999). Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J. Exp. Med. 189, 447-450.
5. FLANAGAN, K., GLOVER, R.T., HORIG, H., YANG, W., and KAUFMAN, H.L. (2004). Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response. Vaccine 22, 2894-2903.
6. GIOVARELLI, M., CAPPELLO, P., FORNI, G., SALCEDO, T., MOORE, P.A., LEFLEUR, D.W., NARDELLI, B., CARLO, E.D., LOLLINI, P.L., RUBEN, S., ULLRICH, S., GAROTTA, G., and MUSIANI, P. (2000). Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J. Immunol. 164, 3200-3206.
7. HEINZERLING, L.M., FEIGE, K., RIEDER, S., AKENS, M.K., DUMMER, R., STRANZINGER, G., and MOELLING, K. (2001). Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J. Mol. Med. 78, 692-702.
8. HEINZERLING, L., DUMMER, R., PAVLOVIC, J., SCHULTZ, J., BURG, G., and MOELLING, K. (2002). Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice. Exp. Dermatol. 11, 232-240.
9. HEINZERLING, L., BURG, G., DUMMER, R., MAIER, T., OBERHOLZER, P.A., SCHULTZ, J., ELZAOUK, L., PAVLOVIC, J., and MOELLING, K. (2005). Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: Clinical efficacy. Hum. Gene Ther. 16, 35-48.
10. IMBODEN, M., SHI, F., PUGH, T.D., FREUD, A.G., THOM, N.J., HANK, J.A., HAO, Z., STAELIN, S.T., SONDEL, P.M., and MAHVI, D.M. (2003). Safety of interleukin-12 gene therapy against cancer: A murine biodistribution and toxicity study. Hum. Gene Ther. 14, 1037-1048.
11. KEYSER, J., SCHULTZ, J., LADELL, K., ELZAOUK, L., HEINZERLING, L., PAVLOVIC, J., and MOELLING, K. (2004). IP-10-encoding plasmid DNA therapy exhibits anti-tumor and anti-metastatic efficiency. Exp. Dermatol. 13, 380-390.
12. KIRK, C.J., HARTIGAN-O'CONNOR, D., and MULE, J.J. (2001). The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res. 61, 8794-8802.
13. LAKKIS, F.G., ARAKELOV, A., KONIECZNY, B.T., and INOUE, Y. (2000). Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat. Med. 6, 686-688.
14. LEE, K., OVERWIJK, W.W., O'TOOLE, M., SWINIARSKI, H., RESTIFO, N.P., DORNER, A.J., WOLF, S.F., and STURMHOEFEL, K. (2000). Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses. J. Interferon Cytokine Res. 20, 589-596.
15. MARSLAND, B.J., BATTIG, P., BAUER, M., RUEDL, C., LASSING, U., BEERLI, R.R., DIETMEIER, K., IVANOVA, L., PFISTER, T., VOGT, L., NAKANO, H., NEMBRINI, C., SAUDAN, P., KOPF, M., and BACHMANN, M.F. (2005). CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity 22, 493-505.
16. MORINI, M., ALBINI, A., LORUSSO, G., MOELLING, K., LU, B., CILLI, M., FERRINI, S., and NOONAN, D.M. (2004). Prevention of angiogenesis by naked DNA IL-12 gene transfer: Angioprevention by immunogene therapy. Gene Ther. 11, 284-291.
17. NAWRATH, M., PAVLOVIC, J., DUMMET, R., SCHULTZ, J., STRACK, B., HEINRICH, J., and MOELLING, K. (1999). Reduced melanoma tumor formation in mice immunized with DNA expressing the melanoma-specific antigen gp100/pmel17. Leukemia 13(Suppl. 1), S48-S51.
18. NAWRATH, M., PAVLOVIC, J., and MOELLING, K. (2001). Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model. J. Mol. Med. 79, 133-142.
19. NOMURA, T., HASEGAWA, H., KOHNO, M., SASAKI, M., and FUJITA, S. (2001). Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1 alpha chemokine genes. Int. J. Cancer 91, 597-606.
20. OKADA, N., IIYAMA, S., OKADA, Y., MIZUGUCHI, H., HAYAKAWA, T., NAKAGAWA, S., MAYUMI, T., FUJITA, T., and YAMAMOTO, A. (2005). Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. Cancer Gene Ther. 12, 72-83.
21. RAKHMILEVICH, A.L., JANSSEN, K., TURNER, J., CULP, J., and YANG, N.S. (1997). Cytokine gene therapy of cancer using gene gun technology: Superior antitumor activity of interleukin-12. Hum. Gene Ther. 8, 1303-1311.
22. SALGALLER, M.L., AFSHAR, A., MARINCOLA, F.M., RIVOLTINI, L., KAWAKAMI, Y., and ROSENBERG, S.A. (1995). Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res. 55, 4972-4979.
23. SCHULTZ, J., PAVLOVIC, J., STRACK, B., NAWRATH, M., and MOELLING, K. (1999). Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA. Hum. Gene Ther. 10, 407-417.
24. SCHULTZ, J., HEINZERLING, L., PAVLOVIC, J., and MOELLING, K. (2000a). Induction of long-lasting cytokine effect by injection of IL-12 encoding plasmid DNA. Cancer Gene Ther. 7, 1557-1565.
25. SCHULTZ, J., PAVLOVIC, J., and MOELLING, K. (2000b). Immune modulation in cancer using DNA inoculation: Antitumour effect of interleukin-12. Dev. Biol. (Basel) 104, 109-114.
26. SHARMA, S., STOLINA, M., LUO, J., STRIETER, R.M., BURDICK, M., ZHU, L.X., BATRA, R.K., and DUBINETT, S.M. (2000). Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol. 164, 4558-4563.
27. SHARMA, S., YANG, S.C., HILLINGER, S., ZHU, L.X., HUANG, M., BATRA, R.K., LIN, J.F., BURDICK, M.D., STRIETER, R.M., and DUBINETT, S.M. (2003). SLC/CCL21-mediated anti-tumor responses require IFNγ, MIG/CXCL9 and IP-10/CXCL10. Mol. Cancer 2, 22.
28. TRINCHIERI, G. (1994). Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84, 4008-4027.
29. TRINCHIERI, G. (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133-146.
30. VICARI, A.P., AIT-YAHIA, S., CHEMIN, K., MUELLER, A., ZLOTNIK, A., and CAUX, C. (2000). Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J. Immunol. 165, 1992-2000.
31. VOEST, E.E., KENYON, B.M., O'REILLY, M.S., TRUITT, G., D'AMATO, R.J., and FOLKMAN, J. (1995). Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87, 581-586.
32. YANG, S.C., HILLINGER, S., RIEDL, K., ZHANG, L., ZHU, L., HUANG, M., ATIANZAR, K., KUO, B.Y., GARDNER, B., BATRA, R.K., STRIETER, R.M., DUBINETT, S.M., and SHARMA, S. (2004). Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin. Cancer Res. 10, 2891-2901.